-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Orthopoxvirus
- Others
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Virus Protease
- Antiviral intermediates
(±)-BI-D
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/1416258-16-6.gif)
| Category | HIV Protease |
| CAS | 1416258-16-6 |
| Description | Approximately 2.4-2.9 μM of BI-D was required to inhibit 50% of HIV-Luc infection of WT and Hdgfrp2 KO cells, while the IC50 decreased dramatically, to 160-200 nM, in Psip1 and double-KO cells. |
Product Information
| Synonyms | (±)-BI-D; BI-D; BI D; BID |
| IUPAC Name | 2-[4-(3,4-dihydro-2H-chromen-6-yl)-2-methylquinolin-3-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid |
| Molecular Weight | 405.49 |
| Molecular Formula | C25H27NO4 |
| Canonical SMILES | CC1=NC2=CC=CC=C2C(=C1C(C(=O)O)OC(C)(C)C)C3=CC4=C(C=C3)OCCC4 |
| InChI | InChI=1S/C25H27NO4/c1-15-21(23(24(27)28)30-25(2,3)4)22(18-9-5-6-10-19(18)26-15)17-11-12-20-16(14-17)8-7-13-29-20/h5-6,9-12,14,23H,7-8,13H2,1-4H3,(H,27,28) |
| InChIKey | ZFERZAMPQIXCPM-UHFFFAOYSA-N |
| Boiling Point | 587.3±50.0 °C at 760 mmHg |
| Flash Point | 309.0±30.1 °C |
| Purity | >98% |
| Density | 1.2±0.1 g/cm3 |
| Solubility | In vitro: 10 mM in DMSO |
| Appearance | Light yellow to yellow (Solid) |
| Storage | Powder: -20°C: 3 years 4°C: 2 years In solvent: -80°C: 6 months -20°C: 1 month |
| Index Of Refraction | 1.610 |
| In Vitro | Approximately 2.4-2.9 μM of BI-D was required to inhibit 50% of HIV-Luc infection of WT and Hdgfrp2 KO cells, while the IC50 decreased dramatically, to 160-200 nM, in Psip1 and double-KO cells |
| Target | HIV; HIV Integrase |
| Vapor Pressure | 0.0±1.7 mmHg at 25°C |
